2012 Annual Meeting | Patient Safety Colloquium

Date Sunday 04/22/12

Time 09:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Colloquium

Director(s) Samuel A. Frank, MD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be able to identify, assess, and implement key patient safety features of common general-purpose technological devices, as well as specific medically focused technological devices; analyze the medical benefits and legal risks to various patient-to-provider electronic communications methods so as to improve patient access to the physician without assuming undue risk; and assess and improve various provider-to-provider communications methods so as to improve the safety of patient care.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Interactive

Program Evaluations

Event Timeline
09:00 AM - 09:10 AM		Introduction Samuel A. Frank, MD, F�鶹��ýӳ��
09:10 AM - 09:40 AM		Presentation of Safety Awards Charles C. Flippen II, MD, F�鶹��ýӳ��
09:40 AM - 10:15 AM		Safely Communicating with Our Colleagues Peter S. Masny, MD
10:15 AM - 10:30 AM		Break
10:30 AM - 11:10 AM		Patient Safety in Partnership with Our Patients Daniel Hoch, MD, PhD, F�鶹��ýӳ��
11:10 AM - 11:50 AM		Is There An App for That? Ethical and Legal Issues in Using Electronic Media to Communicate with Patients and Providers Daniel G. Larriviere, MD, JD, F�鶹��ýӳ��
11:50 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Samuel A. Frank, MD, F�鶹��ýӳ��	Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for uniQure. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Frank has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Frank has received research support from Huntington's Disease Society of America. The institution of Dr. Frank has received research support from Roche/Genentech. The institution of Dr. Frank has received research support from CHDI Foundation. The institution of Dr. Frank has received research support from Huntington Study Group. The institution of Dr. Frank has received research support from Cerevel.
Daniel G. Larriviere, MD, JD, F�鶹��ýӳ��	Dr. Larriviere has nothing to disclose.
Daniel Hoch, MD, PhD, F�鶹��ýӳ��	No disclosure on file
Peter S. Masny, MD	No disclosure on file
Charles C. Flippen II, MD, F�鶹��ýӳ��	Dr. Flippen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Carelon. Dr. Flippen has a non-compensated relationship as a committee member with American Headache Society that is relevant to �鶹��ýӳ�� interests or activities. Dr. Flippen has a non-compensated relationship as a committee/task force member with American Neurological Association that is relevant to �鶹��ýӳ�� interests or activities.